Literature DB >> 17714779

Immunosuppression by placental indoleamine 2,3-dioxygenase: a role for mesenchymal stem cells.

B J Jones1, G Brooke, K Atkinson, S J McTaggart.   

Abstract

BACKGROUND/
OBJECTIVES: Mesenchymal stem cells (MSC) can be isolated from human placenta and have the potential to contribute to the immunosuppressive properties of placental tissue. The objectives of this study were to investigate the phenotype and differentiation characteristics of MSC derived from human placenta and evaluate the role of the tryptophan degrading enzyme, indoleamine 2,3 dioxygenase (IDO), in mediating their immunosuppressive affect.
METHODS: MSC obtained from placental tissue (pMSC) were characterised using flow cytometry and tested for multipotency by determining differentiation into all mesenchymal lineages. The immunosuppressive properties of pMSC were tested in allogeneic mixed lymphocyte reactions and IDO expression and activity were measured by semi-quantitative real-time PCR and HPLC respectively.
RESULTS: Multipotent stem cells were isolated from placenta and displayed chondrogenic, osteogenic and limited adipogenic differentiation. Cell surface antigen expression of pMSC was similar to bone marrow MSC (bMSC) with lack of the haematopoietic and common leukocyte markers (CD34, CD45), and expression of adhesion (CD29, CD166, CD44) and stem cell (CD 90, CD105, CD73) markers. Placental MSC were suppressive of allogeneic T-cell proliferation, an effect which was intensified following IDO induction by IFN-gamma. Replenishment of tryptophan or treatment with the IDO-blocker, 1-methyl-tryptophan (1-MT), attenuated the immunosuppressive action of pMSC.
CONCLUSIONS: These results suggest that placental tissue contains MSC, which are phenotypically and functionally similar to bMSC, and that IDO is a key mediator of their immunosuppressive effect. Further investigation is needed to determine if pMSC function effects pregnancy outcome.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17714779     DOI: 10.1016/j.placenta.2007.07.001

Source DB:  PubMed          Journal:  Placenta        ISSN: 0143-4004            Impact factor:   3.481


  42 in total

1.  Stromal cells from term fetal membrane are highly suppressive in allogeneic settings in vitro.

Authors:  H Karlsson; T Erkers; S Nava; S Ruhm; M Westgren; O Ringdén
Journal:  Clin Exp Immunol       Date:  2012-03       Impact factor: 4.330

2.  Treatment of Spinocerebellar Ataxia With Mesenchymal Stem Cells: A Phase I/IIa Clinical Study.

Authors:  Yun-An Tsai; Ren-Shyan Liu; Jiing-Feng Lirng; Bang-Hung Yang; Chin-Hao Chang; Yi-Chen Wang; Yu-Shan Wu; Jennifer Hui-Chun Ho; Oscar K Lee; Bing-Wen Soong
Journal:  Cell Transplant       Date:  2017-02-14       Impact factor: 4.064

3.  Points to Consider in Designing Mesenchymal Stem Cell-Based Clinical Trials.

Authors:  Gary Brooke; Tony Rossetti; Nina Ilic; Patricia Murray; Sonia Hancock; Rebecca Pelekanos; Kerry Atkinson
Journal:  Transfus Med Hemother       Date:  2008-07-21       Impact factor: 3.747

4.  Mesenchymal stromal cells from human perinatal tissues: From biology to cell therapy.

Authors:  Karen Bieback; Irena Brinkmann
Journal:  World J Stem Cells       Date:  2010-08-26       Impact factor: 5.326

Review 5.  Placental mesenchymal stromal cells as an alternative tool for therapeutic angiogenesis.

Authors:  Suja Ann Mathew; Charuta Naik; Paul A Cahill; Ramesh R Bhonde
Journal:  Cell Mol Life Sci       Date:  2019-08-29       Impact factor: 9.261

6.  Isolation and characterisation of mesenchymal stem cells derived from human placenta tissue.

Authors:  Shalini Vellasamy; Pratheep Sandrasaigaran; Sharmili Vidyadaran; Elizabeth George; Rajesh Ramasamy
Journal:  World J Stem Cells       Date:  2012-06-26       Impact factor: 5.326

Review 7.  The role of placental tryptophan catabolism.

Authors:  Peter Sedlmayr; Astrid Blaschitz; Roland Stocker
Journal:  Front Immunol       Date:  2014-05-19       Impact factor: 7.561

8.  Human T cells upregulate CD69 after coculture with xenogeneic genetically-modified pig mesenchymal stromal cells.

Authors:  Jiang Li; Oleg Andreyev; Man Chen; Michael Marco; Hayato Iwase; Cassandra Long; David Ayares; Zhongyang Shen; David K C Cooper; Mohamed B Ezzelarab
Journal:  Cell Immunol       Date:  2013-08-29       Impact factor: 4.868

9.  Cellular therapy for repair of cardiac damage after acute myocardial infarction.

Authors:  Matthew M Cook; Katarina Kollar; Gary P Brooke; Kerry Atkinson
Journal:  Int J Cell Biol       Date:  2009-03-29

10.  Therapy of experimental type 1 diabetes by isolated Sertoli cell xenografts alone.

Authors:  Francesca Fallarino; Giovanni Luca; Mario Calvitti; Francesca Mancuso; Claudio Nastruzzi; Maria C Fioretti; Ursula Grohmann; Ennio Becchetti; Anne Burgevin; Roland Kratzer; Peter van Endert; Louis Boon; Paolo Puccetti; Riccardo Calafiore
Journal:  J Exp Med       Date:  2009-10-12       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.